AI assistant
Innate Pharma — Share Issue/Capital Change 2010
Apr 8, 2010
1440_dva_2010-04-08_217de26c-4f18-4be3-89c2-756803ead05e.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS AT MARCH 31, 2010
Marseilles, April 8, 2010
Pursuant to the article L. 233-8 II of the French « Code de Commerce » and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") charter, Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 – IPH) releases its total number of shares outstanding as well as its voting rights as at March 31, 2010:
Total number of shares outstanding: 37,679,934 Voting rights: 37,679,934
About Innate Pharma:
Innate Pharma S.A. is a clinical-stage biopharmaceutical company developing first-in-class immunotherapy drugs for cancer and other severe diseases. The Company was incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006. The Company has two drug candidates currently in Phase II clinical trials. Two of its preclinical programs are out-licensed to Novo Nordisk A/S.
Innate Pharma is based in Marseilles, France, and had 80 employees as at December 31, 2009.
Learn more about Innate-Pharma at www.innate-pharma.com.
Practical Information about Innate Pharma shares:
| ISIN code | FR0010331421 |
|---|---|
| Ticker code | IPH |
Disclaimer:
This press release contains certain forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. For a discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Document de Reference prospectus filed with the AMF, which is available on the AMF website (http://www.amf-france.org) or on Innate Pharma's website.
This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.
For additional information, please contact:
Laure-Hélène Mercier Director, Investor Relations Phone: +33 (0)4 30 30 30 87 Mobile: +33 (0)6 64 18 99 59 [email protected] [email protected]
Innate Pharma Alize Public Relations Caroline Carmagnol Phone: +33 (0)1 41 22 07 31